Four GBL Product Makers Receive FDA Warning Letter/Recall Request
This article was originally published in The Tan Sheet
Executive Summary
FDA sent a warning letter and request for recall to four manufacturers of products containing gamma-butyrolactone (GBL) Jan. 27. The agency, in a Jan. 21 "Talk Paper," had cautioned dietary supplement producers it would proceed with regulatory action if they did not voluntarily recall products containing GBL, which can convert to gamma-hydroxybutyrate (GHB), a "very potent" unapproved drug ("The Tan Sheet" Jan. 25, p. 6).